Search
Use the filters to narrow by type of content
Looking for a Publication? Search the bibliography for: publications relationship between improvements fatigue signs symptoms active psoriatic arthritis
Webinar: The Value of Plain Language Summaries in Health Economics and Outcomes Research Share on: Wednesday, May 24, 2023 Commercialization success depends not only on developing rigorous scientific evidence that demonstrates your product’s safety, …
Webinar: Beyond Controlling for Confounding Share on: Thursday, September 27, 2018, 10 - 11am Watch the Recording Going One Step Further in Observational Studies: Design Strategies Randomized clinical trials (RCTs) are the gold standard to quantify the …
… In the end, studies showed that a similar risk exists between FORTEO® users and their comparators, or the general …
Peter Wirth Business Development and Marketing Headquarters - Research Triangle Park, North Carolina, USA BS, Pharmacy Albany College of Pharmacy and Health Sciences, Albany, NY Peter Wirth is Vice President of Business Development at RTI-HS and leads the …
… analysis Our Approach From design to deliverables, publications , and ongoing support, we develop and validate … and transparent model Developing documents and publications to communicate the value of your product …
Navigating market access pathways across European Union markets in 2025 and beyond What do the joint clinical assessments (JCA) in Europe mean for your pharma or medtech company? The parallel paths of the joint clinical assessment process and the …
RTI Releases 2023 Corporate Responsibility and Sustainability Report Share on: February 7, 2024 Institute commits additional $9 million to internal sustainability investments to reduce GHG emissions RTI International, a nonprofit research institute, has …
Collaborative Regulatory RWE Research Through our Barcelona based team, we are a partner center of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) which is led by the European Medicines Agency. We are dedicated to …
… analysis of the long-term effect of Tolvaptan in patients between 56 and 65 years with Autosomal Dominant Polycystic …
Meaningful Work From understanding the cost-effectiveness of treatments to helping reduce risks to patients to ensuring that patient preference is considered in the development of new therapies—we are passionate about what we do. Our scientists actively …